Literature DB >> 21429184

Hepatocyte growth factor levels in Legionella pneumonia: a retrospective study.

Futoshi Higa1, Morikazu Akamine, Makoto Furugen, Kenji Hibiya, Michio Koide, Maki Tamayose, Yuichiro Tamaki, Syusaku Haranaga, Noriko Arakaki, Satomi Yara, Masao Tateyama, Jiro Fujita.   

Abstract

BACKGROUND: Hepatocyte growth factor (HGF) is known to be involved in the resolution of pulmonary inflammation and repair of acute lung injury. Legionella pneumonia is sometimes complicated by acute lung injury. Our study aimed to determine the role of serum HGF levels in Legionella pneumonia.
METHODS: Sera from patients with Legionella pneumonia (42 cases), other bacterial pneumonia (33 cases), pulmonary tuberculosis (19 cases), and normal controls (29 cases) were collected. The serum HGF levels for each serum sample were determined by sandwich ELISA. Clinical and laboratory data were collected by reviewing the medical charts.
RESULTS: Serum HGF levels were higher in patients with Legionella pneumonia than in those with other bacterial pneumonia, pulmonary tuberculosis, and controls. The HGF levels were compared with white blood cell counts, C-reactive protein, Alanine amino-transferase, and lactate dehydrogenase (LDH). The HGF levels were correlated to serum LDH levels. Moreover, serum HGF levels were significantly higher in non-survivors than in survivors.
CONCLUSIONS: HGF levels increased in severer pneumonia caused by Legionella, suggesting that HGF might play a significant role in the Legionella pneumonia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21429184      PMCID: PMC3072943          DOI: 10.1186/1471-2334-11-74

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


  14 in total

1.  Alveolar macrophages that phagocytose apoptotic neutrophils produce hepatocyte growth factor during bacterial pneumonia in mice.

Authors:  K Morimoto; H Amano; F Sonoda; M Baba; M Senba; H Yoshimine; H Yamamoto; T Ii; K Oishi; T Nagatake
Journal:  Am J Respir Cell Mol Biol       Date:  2001-05       Impact factor: 6.914

2.  Hepatocyte growth factor is a better indicator of therapeutic response than C-reactive protein within the first day of treatment in pneumonia.

Authors:  Hossein Abednazari; Junyang Xu; Eva Millinger; Lars Brudin; Pia Forsberg; Fariba Nayeri
Journal:  Chemotherapy       Date:  2006-08-04       Impact factor: 2.544

3.  Elevated serum hepatocyte growth factor/scatter factor levels in inflammatory lung disease.

Authors:  J Maeda; N Ueki; T Hada; K Higashino
Journal:  Am J Respir Crit Care Med       Date:  1995-11       Impact factor: 21.405

4.  Hepatocyte growth factor is produced by blood and alveolar neutrophils in acute respiratory failure.

Authors:  Sandrine Jaffré; Monique Dehoux; Catherine Paugam; Alain Grenier; Sylvie Chollet-Martin; Jean-Baptiste Stern; Jean Mantz; Michel Aubier; Bruno Crestani
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-02       Impact factor: 5.464

5.  Exhaled breath condensate and serum levels of hepatocyte growth factor in pneumonia.

Authors:  F Nayeri; E Millinger; I Nilsson; L Brudin; P Forsberg
Journal:  Respir Med       Date:  2002-02       Impact factor: 3.415

Review 6.  Keratinocyte and hepatocyte growth factors in the lung: roles in lung development, inflammation, and repair.

Authors:  Lorraine B Ware; Michael A Matthay
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-05       Impact factor: 5.464

7.  Hepatocyte growth factor and keratinocyte growth factor in the pulmonary edema fluid of patients with acute lung injury. Biologic and clinical significance.

Authors:  G M Verghese; K McCormick-Shannon; R J Mason; M A Matthay
Journal:  Am J Respir Crit Care Med       Date:  1998-08       Impact factor: 21.405

8.  Clinical features and predictors of mortality in admitted patients with community- and hospital-acquired legionellosis: a Danish historical cohort study.

Authors:  Sanne Jespersen; Ole S Søgaard; Henrik C Schønheyder; Michael J Fine; Lars Ostergaard
Journal:  BMC Infect Dis       Date:  2010-05-21       Impact factor: 3.090

9.  Hepatocyte growth factor (HGF) in patients with pneumonia: a comparison between survivors and non-survivors.

Authors:  F Nayeri; I Nilsson; G Skude; L Brudin; C Söderström
Journal:  Scand J Infect Dis       Date:  1998

10.  Hepatocyte growth factor may act as an early therapeutic predictor in pneumonia.

Authors:  Fariba Nayeri; Lars Brudin; Johan Darelid; Ingela Nilsson; Aril Fryden; Claes Söderström; Pia Forsberg
Journal:  Scand J Infect Dis       Date:  2002
View more
  3 in total

1.  Hepatocyte growth factor can guide treatment of Mycoplasma pneumoniae pneumonia in children.

Authors:  Lun Qin Liu; Zhi Hua Wang; Hai Yun Yao
Journal:  Exp Ther Med       Date:  2020-03-12       Impact factor: 2.447

2.  Time evolution of cytokine profiles associated with mortality in COVID-19 hospitalized patients.

Authors:  Laura Sánchez-de Prada; Óscar Gorgojo-Galindo; Inmaculada Fierro; Ana María Martínez-García; Guillermo Sarmentero-López de Quintana; Rocío Gutiérrez-Bustillo; María Teresa Pelaez-Jareño; Elisa Álvarez-Fuente; Esther Gómez-Sánchez; Eduardo Tamayo; Álvaro Tamayo-Velasco; Marta Martín-Fernández
Journal:  Front Immunol       Date:  2022-09-27       Impact factor: 8.786

3.  The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients.

Authors:  Matthieu Perreau; Madeleine Suffiotti; Pedro Marques-Vidal; Aurelie Wiedemann; Yves Levy; Cédric Laouénan; Jade Ghosn; Craig Fenwick; Denis Comte; Thierry Roger; Jean Regina; Peter Vollenweider; Gerard Waeber; Mauro Oddo; Thierry Calandra; Giuseppe Pantaleo
Journal:  Nat Commun       Date:  2021-08-09       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.